Prevalence of <i>Mycobacterium tuberculosis</i> infection in patients with chronic kidney disease and its related factors analysis

ZHU Qianying; CHENG Yao; TANG Jian; WU Guihui

doi:10.7619/jcmp.20201820

Journal of Clinical Medicine in Practice > 2021 > 25(7): 102-106. > DOI: 10.7619/jcmp.20201820

ZHU Qianying, CHENG Yao, TANG Jian, WU Guihui. Prevalence of Mycobacterium tuberculosis infection in patients with chronic kidney disease and its related factors analysis[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 102-106. DOI: 10.7619/jcmp.20201820

Citation:

PDF (650 KB)

Prevalence of Mycobacterium tuberculosis infection in patients with chronic kidney disease and its related factors analysis

1.
Department of Nephrology, Yucheng District People's Hospital of Ya'an City, Second People's Hospital of Ya'an City, Ya'an, Sichuan, 625000
2.
Department of Tuberculosis, Chengdu City Public Health Clinical Medical Center, Chengdu, Sichuan, 610061

More Information

Received Date: December 27, 2020
Available Online: April 20, 2021
Published Date: April 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To analyze the prevalence and related factors of Mycobacterium tuberculosis infection in patients with chronic kidney disease(CKD).
Methods A total of 327 CKD patients were selected as research objects. The factors that may affect CKD patients with Mycobacterium tuberculosis infection were collected, and the patients were divided into two groups according to whether they were combined with Mycobacterium tuberculosis infection or not. The above-mentioned factors were compared between the two groups, and the comprehensive effect of each factor was judged by multivariate Logistic regression analysis.
Results A total of 63 cases (19.27%) of 327 CKD patients in this survey were infected by Mycobacterium tuberculosis. The results of multivariate Logistic regression analysis showed that female (OR=0.710, 95%CI, 0.526 to 0.959), serum albumin ≥35 g/L (OR=0.689, 95%CI, 0.536 to 0.886), 25-hydroxyvitamin D≥30 nmol/L (OR=0.744, 95%CI, 0.555 to 0.996) were protective factors for Mycobacterium tuberculosis infection in CKD patients, while age ≥60 (OR=1.863, 95%CI, 1.286 to 2.698), history of exposure to tuberculosis (OR=1.654, 95%CI=1.183~2.312), history of smoking (OR=1.895, 95%CI, 1.300 to 2.760), types of antibiotics usage>2 (OR=2.250, 95%CI, 1.328 to 3.812), the use of immunosuppressive agents (OR=2.065, 95%CI, 1.417 to 3.008) were risk factors (P < 0.05).
Conclusion The infection rate of Mycobacterium tuberculosis in CKD patients is relatively high, which is mainly affected by the patient's gender, serum albumin, 25-hydroxyvitamin D, age, history of tuberculosis exposure, smoking history, types of antibiotics, and use of immunosuppressants.
- chronic kidney disease,
- Mycobacterium tuberculosis,
- influencing factors,
- 25-hydroxyvitamin,
- serum albumin

FullText(HTML)

References (19)

References

[1]	李燕, 杨海蓉, 贺艳, 等. 湖南省慢性肾脏病流行病学调查[J]. 湖南师范大学学报: 医学版, 2018, 15(3): 180-183. doi: 10.3969/j.issn.1673-016X.2018.03.054
[2]	CHEN T K, KNICELY D H, GRAMS M E. Chronic kidney disease diagnosis and management: a review[J]. JAMA, 2019, 322(13): 1294-1304. doi: 10.1001/jama.2019.14745
[3]	WANNER C, LACHIN J M, INZUCCHI S E, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease[J]. Circulation, 2018, 137(2): 119-129. doi: 10.1161/CIRCULATIONAHA.117.028268
[4]	CAHUAYME-ZUNIGA L J, BRUST K B. Mycobacterial infections in patients with chronic kidney disease and kidney transplantation[J]. Adv Chronic Kidney Dis, 2019, 26(1): 35-40. doi: 10.1053/j.ackd.2018.09.004
[5]	SAITO N, YOSHⅡ Y, KANEKO Y, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease[J]. BMC Infect Dis, 2019, 19(1): 374. doi: 10.1186/s12879-019-4010-7
[6]	MYALL K, MILBURN H J. An update on the management of latent tuberculosis infection and active disease in patients with chronic kidney disease[J]. Pol Arch Intern Med, 2017, 127(10): 681-686. http://europepmc.org/abstract/MED/28837544
[7]	王海燕, 王梅. 慢性肾脏病及透析的临床实践指南[M]. 北京: 人民卫生出版社, 2003: 7-7.
[8]	周林, 刘二勇, 陈明亭, 等. 认真执行卫生行业新标准努力提升结核病防控质量[J]. 中国防痨杂志, 2018, 40(3): 231-233. doi: 10.3969/j.issn.1000-6621.2018.03.002
[9]	MORAN E, BAHARANI J, DEDICOAT M, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease[J]. J Infect, 2018, 77(4): 291-295. doi: 10.1016/j.jinf.2018.06.003
[10]	BARDENHEIER B H, PAVKOV M E, WINSTON C A, et al. Prevalence of tuberculosis disease among adult US-bound refugees with chronic kidney disease[J]. J Immigr Minor Health, 2019, 21(6): 1275-1281. doi: 10.1007/s10903-018-00852-8
[11]	ABAD C L R, RAZONABLE R R. Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases[J]. Clin Transplant, 2018, 32(6): e13259. doi: 10.1111/ctr.13259
[12]	袁发焕, 赵生家. 1069例慢性肾衰患者合并结核病的临床研究[J]. 西部医学, 2003, 1(3): 199-201. doi: 10.3969/j.issn.1672-3511.2003.03.003
[13]	RAFIEI N, WILLIAMS J, MULLEY W R, et al. Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort[J]. Nephrology: Carlton, 2019, 24(5): 569-574. doi: 10.1111/nep.13386
[14]	SANDUL A L, NWANA N, HOLCOMBE J M, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection[J]. Clin Infect Dis, 2017, 65(7): 1085-1093. doi: 10.1093/cid/cix505
[15]	HODEL N C, HAMAD A, PRAEHAUSER C, et al. The epidemiology of chronic kidney disease and the association with non-communicable and communicable disorders in a population of sub-Saharan Africa[J]. PloS one, 2018, 13(10): 205326-205329. http://www.ncbi.nlm.nih.gov/pubmed/30379902
[16]	MAYITO J, ANDIA I, BELAY M, et al. Anatomic and cellular niches for Mycobacterium tuberculosis in latent tuberculosis infection[J]. J Infect Dis, 2019, 219(5): 685-694. doi: 10.1093/infdis/jiy579
[17]	KIM M Y, BOO S, YOO M, et al. Impact of chronic kidney disease among Korean adults with chronic obstructive pulmonary disease[J]. Int Urol Nephrol, 2017, 49(7): 1225-1232. doi: 10.1007/s11255-017-1572-4
[18]	WHITWORTH H S, BADHAN A, BOAKYE A A, et al. Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study[J]. Lancet Infect Dis, 2019, 19(2): 193-202. doi: 10.1016/S1473-3099(18)30613-3
[19]	NOVITA B D, PRANOTO A, WURYANI, et al. A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients[J]. Indian J Tuberc, 2018, 65(3): 252-256. doi: 10.1016/j.ijtb.2017.05.008

[1]	YANG Zhongxin, ZHOU Ran, HUANG Zhichao, MEI Xiaohan, LI Yijian, YANG Xuefeng, LI Xiaoyu. Circ_0114427 targets microRNA-330-5p to regulate apoptosis and inflammatory response in lipopolysaccharide-induced alveolar epithelial cells[J]. Journal of Clinical Medicine in Practice, 2024, 28(6): 24-29, 36. DOI: 10.7619/jcmp.20232885
[2]	WANG Weiyi, CHEN Ran, YANG Yining. Effect of miR-199a-3p/p38MAPK/NF-κB regulated by sophorae fructus flavonoids on cell proliferation, migration, invasion and secretion of inflammatory factors in breast cancer[J]. Journal of Clinical Medicine in Practice, 2024, 28(4): 1-6, 13. DOI: 10.7619/jcmp.20232432
[3]	MA Cunliang, GENG Qingya. Evaluation value of serum microRNA-19b-3p and microRNA-933 levels on cardiac function and prognosis in elderly patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 63-67. DOI: 10.7619/jcmp.20233416
[4]	Kabinuer·ALIMASI, CHEN Hailin, Aishanjiang·MUHETAER, Maimaitirexiati·SUPAJI, WU Chunping, Anniwaer·MAIMAITI. Effect of long non-coding RNA SLCO4A1-AS1 targeting microRNA-615-5p on the proliferation, apoptosis and inflammatory factors expression in esophageal cancer cells[J]. Journal of Clinical Medicine in Practice, 2024, 28(1): 13-19. DOI: 10.7619/jcmp.20233173
[5]	ZHU Ruiwu, GUO Xiaojie, ZHANG Qing. Relationships of serum microRNA-20a-5p and microRNA-128-3p with cranial nerve development in children with hypoxic-ischemic encephalopathy[J]. Journal of Clinical Medicine in Practice, 2023, 27(22): 50-54. DOI: 10.7619/jcmp.20232224
[6]	CONG Peng, SU Xiangjie, LI Yong. MicroRNA-433-3p regulates malignant biological behavior of pancreatic cancer PANC-1 cells by targeting Smoothened[J]. Journal of Clinical Medicine in Practice, 2023, 27(14): 19-25. DOI: 10.7619/jcmp.20231065
[7]	SI Fengzhi, ZHOU Xu. Effect of microRNA-142-3p targeting tumor necrosis factor-alpha on inflammatory response of human nasal epithelial cells induced by lipopolysaccharide[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 30-34. DOI: 10.7619/jcmp.20223063
[8]	XUE Mei, LIAO Yi, LU Wei. Effects of microRNA-455-3p on airway smooth muscle cells in asthmatic rats by regulating toll-like receptor 4[J]. Journal of Clinical Medicine in Practice, 2022, 26(22): 25-32. DOI: 10.7619/jcmp.20221809
[9]	XU Dongrui, WANG Xiaolong, MA Wenchao, LIU Tongxiang, DONG Yuanbao, YIN Lijuan. Effect of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome on in-stent restenosis after coronary stent implantation[J]. Journal of Clinical Medicine in Practice, 2021, 25(19): 16-19. DOI: 10.7619/jcmp.20211930
[10]	LIU Yue, ZUO Na. Effect of hemodiafiltration on micro-inflammation and nutritional status in maintenance hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2017, (4): 67-70. DOI: 10.7619/jcmp.201704021

Cited By

Get Citation

PDF

XML

Article views (422) PDF downloads (18)

Turn off MathJax

Article Contents

Abstract

References

Prevalence of Mycobacterium tuberculosis infection in patients with chronic kidney disease and its related factors analysis

Abstract

References

Related Articles

Catalog

Prevalence of Mycobacterium tuberculosis infection in patients with chronic kidney disease and its related factors analysis

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content